Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification. Significance: Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes. This article is highlighted in the In This Issue feature, p. 549
1 May 1992 in Irish Journal of Medical Science (1971 -)
This protocol describes a way to rank industries based on a specific set of measures of industry exposure to SARS-CoV-2 in the United States. Note, this protocol extends, “SOEM-X: Measuring industry exposure to SARS-CoV-2 in the United States.”
This protocol describes a way to rank industries based on a specific set of measures of industry exposure to SARS-CoV-2 in the United States. Note, this protocol extends, “SOEM-X: Measuring industry exposure to SARS-CoV-2 in the United States.”
This protocol explains how to generate a novel set of industry-level measures for exposure to SARS-CoV-2 in the United States based on a specific set of occupation-level measures of exposure to SARS-CoV-2 in the United States. Note, this protocol extends the SARS-CoV-2 Occupational Exposure Matrix (SOEM).
This protocol explains how to generate a novel set of industry-level measures for proximity exposure to SARS-CoV-2 in the United States. These measures are derived from a specific set of occupation-level measures of proximity exposure to SARS-CoV-2 in the United States. Note, this protocol is a variant of “SOEM-X: Measuring industry exposure to SARS-CoV-2 in the United States.”